Parkinson-CBD

The database includes the raw data of the article “Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease” (doi.org/10.3390/ijms22168920). The aim of this study was to evaluate the effects of chronic treatment with cannabidiol (CBD) on Parkinson’s disease-associated neurodegenerative and neuroinflammatory processes, and motor deficits in the 6-hydroxydopamine (6-OHDA) model. Moreover, the potential mechanisms by which CBD exerted its effects in this model has been investigated. The database contains the data obtained by the following evaluations: a) immunohistochemical analysis of the extent of nigrostriatal lesion, b) motor performance assessment by cylinder test (at baseline and after 28days), apomorphine-induced rotation test and rotarod test, c) immunohistochemical analysis of neuroinflammatory response - involving microglia and astrocytes - in the substantia nigra pars compacta, investigating both cell activation and polarization, d)co-localization analysis of transient receptor potential cation channel subfamily V member 1 (TRPV1) and ciliary neurotrophic factor (CNTF) expression in astrocytes.

CBD-treated animals showed a reduction of nigrostriatal degeneration accompanied by a damping of the neuroinflammatory response and an improvement of motor performance. In particular, CBD exhibited a preferential action on astrocytes, by activating TRPV1 and enhancing the endogenous neuroprotective response of CNTF. These results overall support the potential therapeutic utility of CBD in PD, as both neuroprotective and symptomatic agent.